Albemarle Corporation Company Profile (NYSE:ALB)

Albemarle Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALB."

Albemarle Corporation declared a quarterly dividend on Monday, July 10th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.32 per share on Monday, October 2nd. This represents a $1.28 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Thursday, September 14th. View Albemarle Corporation's Dividend History.

Albemarle Corporation (NYSE:ALB) released its quarterly earnings data on Monday, August, 7th. The company reported $1.13 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.11 by $0.02. The company earned $737.25 million during the quarter, compared to analyst estimates of $735.50 million. Albemarle Corporation had a net margin of 31.49% and a return on equity of 11.59%. The company's revenue was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.93 earnings per share. View Albemarle Corporation's Earnings History.

Albemarle Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Albemarle Corporation.

Albemarle Corporation updated its FY17 earnings guidance on Monday, August, 7th. The company provided EPS guidance of $4.20-4.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.36. The company issued revenue guidance of $2.90-3.05 billion, compared to the consensus revenue estimate of $2.95 billion.

17 analysts have issued twelve-month target prices for Albemarle Corporation's stock. Their forecasts range from $36.00 to $157.00. On average, they expect Albemarle Corporation's stock price to reach $122.65 in the next twelve months. View Analyst Ratings for Albemarle Corporation.

Here are some recent quotes from research analysts about Albemarle Corporation stock:

• 1. According to Zacks Investment Research, "Albemarle has outperformed the industry it belongs to over a year.  Albemarle remains focused on strengthening its lithium business. It is well placed to leverage strong expected growth in the battery-grade lithium market. The company should also gain from the synergies of Rockwood Holdings acquisition. Albemarle is also divesting non-core assets to boost growth opportunities and focus on its key businesses. Moreover, the company remains committed to deliver incremental returns to shareholders." (10/17/2017)
• 2. UBS AG analysts commented, "Theme was 'potential 'drives everything ALB does'. Batteries store potential energy chemically, until needed to create electrical potential to power devices. Lithium chem. is the primary driver of ALB earnings growth. 2021 targets were introduced for 7-10% organic sales CAGR, primarily from lithium. Average EBITDA margins also targeted to reach 32-35% (vs. 29% 2017e), implying an EBITDA CAGR of 9%-15% (primarily from lithium, which improves margin mix)." (3/22/2017)
• 3. Robert W. Baird analysts commented, "ALB introduced long-term revenue and EBITDA targets displaying strong lithium growth, and raised lithium market growth expectations given increasing electric vehicle and battery demand. Additionally, ALB remains well positioned in its catalyst and bromine businesses, which should provide cash flow for investment in expanded lithium production. We are confident in ALB's ability to ramp lithium production, and believe ALB is the best option to play a multiyear lithium growth cycle given ALB's resources and technical expertise. We remain buyers." (3/17/2017)
• 4. Instinet analysts commented, "We see 4Q as confirmation of ALB's significant leverage to rising lithium pricing, with a majority of 30% q-q EBITDA growth in the segment attributed to price. Price will remain an important contributor in 2017 (+10- 15%) based on contracts already locked for 80% of the business. We do not expect price to be a major source of upside to expectations until 2018+. However, with Li contracts now accounting for three to five years of production, volume ramp is being de-risked as well. Management is now looking to extend contract duration to six to seven years where possible. We do not suggest that EBITDA is riskless, but we would argue that ALB's Lithium business now has a high degree of protection vs. a short-term supply/demand disruption. Ultimately, we believe Li demand will surprise to the upside over next 2-3 years. However, ALB has reasonable protection in case of S/D hiccups, such as major slowdown in the China EV market or new supply hitting the market sooner than expected. We raise our target price to $118 from $102. FY17E EPS at $4.20; FY18E EPS at $4.43." (3/1/2017)

Some companies that are related to Albemarle Corporation include Celanese Corporation (CE), Eastman Chemical Company (EMN), Braskem S.A. (BAK), Westlake Chemical Corporation (WLK), Chemours Company (The) (CC), Olin Corporation (OLN), NewMarket Corporation (NEU), Methanex Corporation (MEOH), Ingevity Corp (NGVT), Quaker Chemical Corp (KWR), Calgon Carbon Corporation (CCC), A. Schulman (SHLM), Koppers Holdings (KOP), Innophos Holdings (IPHS), CSW Industrials (CSWI), Westlake Chemical Partners LP (WLKP), Trecora Resources (TREC) and Enzymotec (ENZY).

Albemarle Corporation's management team includes the folowing people:

• Luther C. Kissam IV, Chairman, President and Chief Executive Officer
• Scott A. Tozier, Chief Financial Officer, Executive Vice President
• Karen G. Narwold, Executive Vice President, Chief Administrative Officer
• Matthew K. Juneau, Executive Vice President, Corporate Strategy
• Donald J. LaBauve Jr., Chief Accounting Officer, Vice President, Corporate Controller
• Jimmy W. Nokes, Lead Independent Director
• Laurie Brlas, Director
• William H. Hernandez, Independent Director
• Douglas L. Maine, Independent Director
• Jerry Kent Masters, Independent Director

Shares of Albemarle Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Albemarle Corporation stock can currently be purchased for approximately $139.66.